A coalition announced yesterday the beginning of a Phase 2b trial of MVA85A, a new investigational vaccine for tuberculosis.
A coalition of groups announced yesterday the beginning of a Phase 2b trial of MVA85A, a new investigational vaccine for tuberculosis (TB). The groups behind the vaccine are Aeras, a US-based non-profit development organization, and the Oxford-Emergent Tuberculosis Consortium, which is a joint venture between the University of Oxford in the UK and Emergent BioSolutions, a US-based pharmaceutical company.
The trial will test MVA85A on approximately 1,400 adults aged 18-50 in Senegal and South Africa who are infected with HIV. MVA85A is designed to boost the response of T-cells. TB is a leading cause of death for people with HIV; people with HIV living in countries where TB is common are twenty times more likely to get TB than those who do not have HIV.